Browse by Audience
MEMBER

Update Your Profile
Member Spotlights
Refer a Member: IASP Champions
Join a Special Interest Group (SIG)
Find a Chapter
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Papers of the Week
Webinars and Podcasts
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Webinars & Podcasts
Curricula
Graduate Opportunities
Events

PATIENT & CAREGIVER

RELIEF News
Resources for Living with Pain
Global Alliance of Partners in Pain Advocacy (GAPPA)
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner

gy2022-1-3
I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / EFFECTIVENESS AND TOLERABILITY OF DRONABINOL USE IN PATIENTS WITH CHRONIC PAIN – A RETROSPECTIVE ANALYSIS OF 12-WEEK OPEN-LABEL REAL-WORLD DATA PROVIDED BY THE GERMAN PAIN E-REGISTRY.

< BACK TO ARCHIVE


Papers: 29 Jan 2022 - 4 Feb 2022


Pharmacology/Drug Development


2022 Feb 01


Pain Med


http://www.ncbi.nlm.nih.gov/pubmed/35104881?dopt=Abstract

EFFECTIVENESS AND TOLERABILITY OF DRONABINOL USE IN PATIENTS WITH CHRONIC PAIN – A RETROSPECTIVE ANALYSIS OF 12-WEEK OPEN-LABEL REAL-WORLD DATA PROVIDED BY THE GERMAN PAIN E-REGISTRY.

Authors

EFFECTIVENESS AND TOLERABILITY OF DRONABINOL USE IN PATIENTS WITH CHRONIC PAIN - A RETROSPECTIVE ANALYSIS OF 12-WEEK OPEN-LABEL REAL-WORLD DATA PROVIDED BY THE GERMAN PAIN E-REGISTRY.
Ueberall MA, Horlemann J, Schuermann N, Kalaba M, Ware MA
Pain Med. 2022 Feb 01.
PMID: 35104881.

Abstract

To evaluate the effectiveness of Δ9-tetrahydrocannabinol (dronabinol, DRO), as an add-on treatment in patients with refractory chronic pain (CP).
Read This Paper